巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Crinetics Pharmaceuticals

CRNX
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Crinetics Pharmaceuticals - 延遲價格・最後更新於 26/01 12:15
最高位
20.290
最低位
18.670
開市價
--
前收市價
19.020
成交量(千)
18.37
成交額(百萬)
2.93
買入
--
賣出
--
每手股數
--
市值(百萬)
901.55
市盈率
--
息率
--
差價
--
52週高低
28.798 - 13.830
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Crinetics Pharmaceuticals
證券代碼
CRNX.US
所屬板塊
Biotechnology
公司業務
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidates include paltusotine which is in clinical development for the treatment of acromegaly and neuroendocrine tumors, or NETs, CRN04777, which is in clinical development for congenital hyperinsulinism, or HI, and CRN04894, which is in clinical development for diseases of excess adrenocorticotrophic hormone, or ACTH, including Cushing's Disease, congenital adrenal hyperplasia, or CAH, and Ectopic ACTH Syndrome, or EAS.
發行量
37590920
公司總部
10222 Barnes Canyon Road, Building No. 2
公司網址
https://www.crinetics.com
公司電郵
IR@crinetics.com
公司電話
+1 858 450-6464
暫無內容

關於

Crinetics Pharmaceuticals(CRNX.US)所屬的行業板塊為Biotechnology。
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidates include paltusotine which is in clinical development for the treatment of acromegaly and neuroendocrine tumors, or NETs, CRN04777, which is in clinical development for congenital hyperinsulinism, or HI, and CRN04894, which is in clinical development for diseases of excess adrenocorticotrophic hormone, or ACTH, including Cushing's Disease, congenital adrenal hyperplasia, or CAH, and Ectopic ACTH Syndrome, or EAS.
詳細公司背景可參考: https://www.crinetics.com